Since the death of 19-year-old Emily Stillman, a foundation named for her has been raising funds for both meningococcal disease and organ donation, as well as spreading awareness.
The Emily Stillman Foundation — started by Alicia and Michael Stillman — has taken busloads of people into Canada to be vaccinated for serogroup B meningococcal disease as part of its awareness campaign.
Prior to October 2014, the Food and Drug Administration had not approved vaccines for the serogroup B meningococcal disease that killed Emily in February 2013. But on Oct. 29, the FDA approved the first serogroup B meningococcal vaccine — Trumenba — for use in people ages 10-25 as a three-dose series. The FDA then approved a second serogroup B meningococcal vaccine — Bexsero — again for people 10-25 years of age, but as a two-dose series.